<DOC>
	<DOCNO>NCT00689741</DOCNO>
	<brief_summary>The purpose phase IIB MedImmune-sponsored study evaluate efficacy HPV-16/18 VLP vaccine prevention infection HPV-16 and/or HPV-18 adolescent young adult woman . A vaccine prevents , even reduces , incidence common type high-risk HPVs , particularly HPV-16 HPV-18 , could result significant reduction incidence cervical cancer cancer-related mortality , well reduction incidence surgical procedure follow abnormal Pap smear .</brief_summary>
	<brief_title>Efficacy Study HPV-16/18 Vaccine ( GSK 580299 ) Prevent HPV-16 and/or -18 Cervical Infection Young Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female include 15 25 year age time screen ( must reach 26th birthday ) Written informed consent obtain subject prior enrolment ( subject legal age consent , write informed consent must also obtain parent legal guardian subject ) Free obvious health problem , establish medical history direct physical examination No 6 lifetime sexual partner prior enrolment Intact uterus Subject must nonchildbearing potential , i.e. , either surgically sterilise , childbearing potential , must abstinent must use effective method birth control 30 day prior vaccination , negative urine pregnancy test must agree continue precaution two month completion vaccination series For subject enrol HPV epidemiology study ( 999910/106 ) subject complete study ( 999910/106 ) &gt; 90 day prior enrolment present study : agreement complete entrance exit study questionnaires concern general personal information , sexual , contraceptive , reproductive gynaecological medical history For subject previously enrol HPV epidemiology study ( complete study entrance questionnaire ) ≤ 90 day prior enrolment present study : agreement complete exit questionnaire . Normal cervical cytology ( Pap smear ) screening , use Cytyc ThinPrep® Pap Test . A normal Pap smear must also adequate interpretation , include presence endocervical cell ; Pap smear normal inadequate interpretation must repeat part protocol Seronegative HPV16 HPV18 antibody ELISA screen HPV DNA PCR negative highrisk HPV type PCR screening . Genotyping specify use reverse line probe assay specific detection highrisk HPV type HPV16 , HPV18 HPV16/18related phylogenetic type Pregnant lactate female Female planning become pregnant first eight month study ( month 08 ) Abnormal vaginal discharge time entry ( subject receive therapy eradicate discharge eligible participate study ) Previous administration component investigational vaccine Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulin and/or blood product within three month ( 90 day ) precede first dose study vaccine plan administration study period Planned administration / administration vaccine foreseen study protocol within 30 day first dose study vaccine . Administration routine Meningococcal , Hepatitis A , Hepatitis B , Influenza , Diphtheria/Tetanus vaccine 8 day first dose study vaccine allow Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period Receiving expect therapy external internal condylomata . Subjects external condylomata require therapy eligible participate study Genital herpes disease involve cervix characterize ( examination history ) extensive external lesion . Subjects history recurrent genital herpes disease characterize limited external lesion eligible participate study History abnormal cervical cytology ( Pap smear ) test ( single prior report ASCUS subsequent normal report ) Treatment cervical disease ablative therapy ( cryotherapy laser ablation ) excisional therapy ( laser cone biopsy , loop excision , coldknife conization ) Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection A family history congenital hereditary immunodeficiency Major congenital defect serious chronic illness History neurologic disorder seizure , exception single febrile seizure childhood Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test Acute disease time enrolment . Oral temperature ≥99.5°F ( ≥37.5°C ) / axillary temperature ≥99.5°F ( 37.5°C ) / rectal temperature ≥100.4°F ( ≥38.0°C ) / tympanic temperature oral set ≥99.5°F ( 37.5°C ) / tympanic temperature rectal setting ≥100.4°F ( ≥38.0°C ) History chronic alcohol consumption and/or intravenous drug abuse within past 2 year Known suspect allergy vaccine component Hepatomegaly , right upper quadrant abdominal pain tenderness</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>vaccine</keyword>
</DOC>